PepGen Ltd
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $6.06
- Today's High:
- $6.4
- Open Price:
- $6.06
- 52W Low:
- $4.32
- 52W High:
- $20
- Prev. Close:
- $6.14
- Volume:
- 38627
Company Statistics
- Market Cap.:
- $153.84 million
- Book Value:
- 6.185
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -22.99%
- Return on Equity TTM:
- -38.82%
Company Profile
PepGen Ltd had its IPO on 2022-05-06 under the ticker symbol PEPG.
The company operates in the Healthcare sector and Biotechnology industry. PepGen Ltd has a staff strength of 54 employees.
Stock update
Shares of PepGen Ltd opened at $6.06 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $6.06 - $6.4, and closed at $6.33.
This is a +3.09% increase from the previous day's closing price.
A total volume of 38,627 shares were traded at the close of the day’s session.
In the last one week, shares of PepGen Ltd have slipped by -2.01%.
PepGen Ltd's Key Ratios
PepGen Ltd has a market cap of $153.84 million, indicating a price to book ratio of 1.6645 and a price to sales ratio of 0.
In the last 12-months PepGen Ltd’s revenue was $0 with a gross profit of $0 and an EBITDA of $-75173000. The EBITDA ratio measures PepGen Ltd's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, PepGen Ltd’s operating margin was 0% while its return on assets stood at -22.99% with a return of equity of -38.82%.
In Q2, PepGen Ltd’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
PepGen Ltd’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.27 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into PepGen Ltd’s profitability.
PepGen Ltd stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of -2.1653. Its price to sales ratio in the trailing 12-months stood at 0.
PepGen Ltd stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $182.09 million
- Total Liabilities
- $16.94 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $1.01 million
- Dividend Payout Ratio
- 0%
PepGen Ltd ended 2024 with $182.09 million in total assets and $0 in total liabilities. Its intangible assets were valued at $182.09 million while shareholder equity stood at $147.28 million.
PepGen Ltd ended 2024 with $0 in deferred long-term liabilities, $16.94 million in other current liabilities, 2000.00 in common stock, $-138697000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $147.03 million and cash and short-term investments were $147.03 million. The company’s total short-term debt was $3,492,000 while long-term debt stood at $0.
PepGen Ltd’s total current assets stands at $150.38 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $1.82 million and inventory worth $0.
In 2024, PepGen Ltd's operating cash flow was $0 while its capital expenditure stood at $1.01 million.
Comparatively, PepGen Ltd paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $6.33
- 52-Week High
- $20
- 52-Week Low
- $4.32
- Analyst Target Price
- $23.2
PepGen Ltd stock is currently trading at $6.33 per share. It touched a 52-week high of $20 and a 52-week low of $20. Analysts tracking the stock have a 12-month average target price of $23.2.
Its 50-day moving average was $6.63 and 200-day moving average was $12.43 The short ratio stood at 3.63 indicating a short percent outstanding of 0%.
Around 6% of the company’s stock are held by insiders while 9776.1% are held by institutions.
Frequently Asked Questions About PepGen Ltd
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that id in Phase I clinical trial to treat individuals with Duchenne muscular dystrophy (DMD). The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is headquartered in Boston, Massachusetts.